Brief: Orgenesis And Theracell Joint Venture To Receive Up To €32 Mln From Greek Government
29/11/2021 12:24
Nov 29 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS AND THERACELL JOINT VENTURE TO RECEIVE UP TO €32
MILLION FROM GREEK GOVERNMENT TO ACCELERATE ROLLOUT OF POCARE
CENTERS AND DEPLOYMENT OF OMPULS
* ORGENESIS INC - JV NAMED A "PRIORITY INVESTMENT OF
STRATEGIC
NATIONAL IMPORTANCE" BY GOVERNMENT OF GREECE
* ORGENESIS INC - AS A RESULT OF DESIGNATION, JV WILL BE
INDUCTED
INTO GREECE'S FAST-TRACK LICENSING AND APPROVAL PROCESS
Source text for Eikon: ID:nGNXqN1hm
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules